

## Supplementary Information

Altered transcriptomes, cell type proportions, and dendritic spine morphology in hippocampus of suicide deaths

Das, Sujan C.<sup>1</sup>, Anton Schulmann<sup>2</sup>, William B. Callor<sup>3</sup>, Leslie Jerominski<sup>7</sup>, Mitradas M. Panicker<sup>4</sup>, Erik D. Christensen<sup>3</sup>, William E. Bunney<sup>5</sup>, Megan E. Williams<sup>6</sup>, Hilary Coon<sup>7</sup>, Marquis P. Vawter<sup>1#</sup>




Figure SF1: Major cell types for which the estimated cell type proportions were determined. Excit=Excitatory Neurons, Inhib=Inhibitory Neurons, Astro=Astrocytes, Oligo=Oligodendrocytes, OPC=Oligodendrocytes Progenitor Cells.




Figure SF2: The effect of age (A) and sex (B) on estimated cell type proportions of excitatory and inhibitory neurons. Excit=excitatory neurons, Inhib= inhibitory neurons, F=females, M=males.

GO:0060079 - excitatory postsynaptic potential (49 genes) Scores: DESeq2\_Final.txt col: 2 pvalue

Cell Width:  Color Range:

Element	Score ▲	QQ Score	Symbol	Name	Multifunc	QQ Multifunc
NPAS4	8.98e-06		<a href="#">NPAS4</a>	neuronal PAS domain protein 4	0.745 (131)	
P2RX6	5.48e-05		<a href="#">P2RX6</a>	purinergic receptor P2X 6	0.687 (109)	
CHRNA1	0.000642		<a href="#">CHRNA1</a>	cholinergic receptor nicotinic alpha 1 subunit	0.805 (116)	
MEF2C	0.00159		<a href="#">MEF2C</a>	myocyte enhancer factor 2C	0.997 (484)	
GLRA2	0.00566		<a href="#">GLRA2</a>	glycine receptor alpha 2	0.893 (126)	
GRIN2C	0.00954		<a href="#">GRIN2C</a>	glutamate ionotropic receptor NMDA type subunit 2C	0.826 (176)	
P2RX4	0.0233		<a href="#">P2RX4</a>	purinergic receptor P2X 4	0.953 (298)	
CHRNB1	0.0513		<a href="#">CHRNB1</a>	cholinergic receptor nicotinic beta 1 subunit	0.731 (104)	
LRRK2	0.0524		<a href="#">LRRK2</a>	leucine rich repeat kinase 2	0.998 (673)	
SLC29A1	0.0622		<a href="#">SLC29A1</a>	solute carrier family 29 member 1 (Augustine blood group)	0.970 (104)	
PPP3CA	0.0843		<a href="#">PPP3CA</a>	protein phosphatase 3 catalytic subunit alpha	0.994 (486)	
GRIN2D	0.0921		<a href="#">GRIN2D</a>	glutamate ionotropic receptor NMDA type subunit 2D	0.846 (189)	
MPP2	0.0981		<a href="#">MPP2</a>	MAGUK p55 scaffold protein 2	0.331 (54)	
GRIN2B	0.104		<a href="#">GRIN2B</a>	glutamate ionotropic receptor NMDA type subunit 2B	0.873 (252)	
MECP2	0.132		<a href="#">MECP2</a>	methyl-CpG binding protein 2	0.979 (398)	
ARRB2	0.136		<a href="#">ARRB2</a>	arrestin beta 2	0.980 (399)	
P2RX5	0.162		<a href="#">P2RX5</a>	purinergic receptor P2X 5	0.679 (127)	
MAPK8IP2	0.189		<a href="#">MAPK8IP2</a>	mitogen-activated protein kinase 8 interacting protein 2	0.723 (131)	
CHRNA7	0.205		<a href="#">CHRNA7</a>	cholinergic receptor nicotinic alpha 7 subunit	0.920 (266)	
CHRNB2	0.206		<a href="#">CHRNB2</a>	cholinergic receptor nicotinic beta 2 subunit	0.956 (244)	
RAB3GAP1	0.206		<a href="#">RAB3GAP1</a>	RAB3 GTPase activating protein catalytic subunit 1	0.949 (177)	
GRIN2A	0.218		<a href="#">GRIN2A</a>	glutamate ionotropic receptor NMDA type subunit 2A	0.924 (331)	
TRPV1	0.235		<a href="#">TRPV1</a>	transient receptor potential cation channel subfamily V member 1	0.989 (340)	
CHRNA5	0.277		<a href="#">CHRNA5</a>	cholinergic receptor nicotinic alpha 5 subunit	0.678 (102)	
OPRM1	0.299		<a href="#">OPRM1</a>	opioid receptor mu 1	0.978 (260)	
GSK3B	0.302		<a href="#">GSK3B</a>	glycogen synthase kinase 3 beta	0.988 (448)	
CHRNE	0.319		<a href="#">CHRNE</a>	cholinergic receptor nicotinic epsilon subunit	0.564 (83)	
SEZ6	0.321		<a href="#">SEZ6</a>	seizure related 6 homolog	0.480 (58)	
GRIK5	0.363		<a href="#">GRIK5</a>	glutamate ionotropic receptor kainate type subunit 5	0.852 (180)	
GSK3A	0.374		<a href="#">GSK3A</a>	glycogen synthase kinase 3 alpha	0.987 (453)	
SNCA	0.376		<a href="#">SNCA</a>	synuclein alpha	0.998 (632)	
GRIN1	0.380		<a href="#">GRIN1</a>	glutamate ionotropic receptor NMDA type subunit 1	0.910 (304)	
ADORA1	0.488		<a href="#">ADORA1</a>	adenosine A1 receptor	0.996 (394)	
S1PR2	0.505		<a href="#">S1PR2</a>	sphingosine-1-phosphate receptor 2	0.770 (126)	
GLRA3	0.507		<a href="#">GLRA3</a>	glycine receptor alpha 3	0.896 (116)	
CHRNA2	0.508		<a href="#">CHRNA2</a>	cholinergic receptor nicotinic alpha 2 subunit	0.628 (90)	
NPFF	0.539		<a href="#">NPFF</a>	neuropeptide FF-amide peptide precursor	0.327 (40)	
P2RX2	0.547		<a href="#">P2RX2</a>	purinergic receptor P2X 2	0.834 (176)	
DRD2	0.578		<a href="#">DRD2</a>	dopamine receptor D2	0.999 (619)	
GRID2	0.587		<a href="#">GRID2</a>	glutamate ionotropic receptor delta type subunit 2	0.830 (161)	
GHRL	0.595		<a href="#">GHRL</a>	ghrelin and obestatin prepropeptide	0.999 (377)	
CDK5	0.645		<a href="#">CDK5</a>	cyclin dependent kinase 5	0.990 (580)	
AKT1	0.718		<a href="#">AKT1</a>	AKT serine/threonine kinase 1	0.997 (725)	
P2RX7	0.839		<a href="#">P2RX7</a>	purinergic receptor P2X 7	0.996 (571)	
GLRB	0.895		<a href="#">GLRB</a>	glycine receptor beta	0.926 (141)	
CELF4	0.910		<a href="#">CELF4</a>	CUGBP Elav-like family member 4	0.743 (148)	
CHRNA4	0.930		<a href="#">CHRNA4</a>	cholinergic receptor nicotinic alpha 4 subunit	0.764 (141)	
CHRNA3	0.960		<a href="#">CHRNA3</a>	cholinergic receptor nicotinic alpha 3 subunit	0.890 (184)	
GRIK2	0.971		<a href="#">GRIK2</a>	glutamate ionotropic receptor kainate type subunit 2	0.928 (170)	

Figure SF3: Details of gene ontology term “GO:0060079-Excitatory Postsynaptic Potential”

Table ST1A: Demographics of subjects.

	Controls (CON)	Suicide Deaths (Sui)	p-value for statistical difference
N	28	22	N/A
Sex	Male= 13, Female=15	Male= 12, Female=10	p=0.57
Age (Mean, Std. Dev)	41.96 (15.41)	39.73 (15.40)	p=0.61
RIN (Mean, Std. Dev), CA1 Tissues	5.41 (1.36)	5.43 (1.65)	p=0.97
PMI (Mean, Std. Dev)	17.41 (6.99)	21.60 (7.02)	*p=0.04
RIN, iPSC-derived NPC	9.5, 9.6	9.7, 9.8	N/A
RIN, iPSC-derived Neurons	10, 10	9.9, 10	N/A

RIN=RNA Integrity Number, PMI=Postmortem Interval, N/A=Not Applicable. Unpaired t-test for age, RIN, and PMI. Chi-square test for sex differences.

Table ST1B: Detailed Demographics of Subjects.

Sex	RIN	PMI (Hours)	Manner of Death	Comorbidity	Toxicology
CON Group					
M	5.6	11	Natural	None Reported	None
M	3.1	19	Natural	Head Injury	Ethanol
M	3.8	17	Accident	None Reported	None
M	3.2	22	Natural	None Reported	None
M	6.2	28.35	Natural	Tremors	None
M	5.2	18	Accident	None Reported	None
M	5.9	15	Accident	None Reported	None
M	6.5	11.6	Accident	None Reported	Ethanol
M	3.1	17.36	Natural	None Reported	None
F	6.9	11.22	Accident	Mild Stroke	Ethanol, Caffeine, Cotinine, Naloxone
F	7.7	9.26	Accident	None Reported	Caffeine, Cotinine, Benzoylcgonine, Codeine, Morphine, Diphenhydramine, 6-MAM
F	4.8	8.2	Accident	None Reported	Ethanol
F	6.2	30.49	Natural	None Reported	Midazolam

F	6.4	27.16	Undetermined	None Reported	Caffeine, Cotinine, Ethanol
F	5.2	14.55	Natural	Delusion	Cyclobenzaprine, 7-Aminoclonazepam
F	5.5	17.3	Homicide	None Reported	Caffeine
F	3.2	24.1	Natural	None Reported	None
F	2.5	28.2	Natural	None Reported	None
F	5.5	22.59	Accident	None Reported	None
F	7.1	25.23	Accident	None Reported	Caffeine, Methadone, Citalopram, EDDP, Amphetamine, Methamphetamine
F	6.4	20	Accident	None Reported	Lorazepam, 7-Amino Clonazepam, 11-hydroxy delta-9 THC, delta-9 carboxy THC, delta-9 THC, Amphetamine, Methamphetamine
M	6.1	8	Natural	None Reported	None
F	5.6	11	Accident	None Reported	Amphetamine, Methamphetamine
M	6.3	18	Accident	None Reported	THC
M	5.9	6	Accident	None Reported	Amphetamine, Methamphetamine, 6-Monoacetyl Morphine, Codeine, Morphine, Benzoylcegonine
F	5.4	13	Accident	None Reported	Amphetamine, Methamphetamine, Morphine, 6-Monoacetyl Morphine
M	6.2	10	Natural	Depression, Anxiety	Ethanol, Caffeine, Isopropanol, Cotinine, Naloxone
F	6.1	24	Natural	Lupus, Chronic Pain	Caffeine, Alprazolam, Delta-9 Carboxy THC, Trazodone, mCPP, Citalopram
Sui Group					
M	3.9	16	Suicide	Depression	Ethanol
M	5.1	24	Suicide	Suicide Ideation and Threats	Ethanol
M	6.3	25	Suicide	None Reported	None
M	6.6	22.42	Suicide	Depression, Anxiety	Trazodone, 7-Aminoclonazepam
M	7.1	18	Suicide	None Reported	None
M	6.7	18.58	Suicide	ADHD, Depression, Suicide Ideation	Amitriptyline
M	4.2	15.17	Suicide	None Reported	Ethanol
M	6.9	16.51	Suicide	None Reported	None
F	6.3	24	Suicide	None Reported	None
F	6.8	43.28	Suicide	None Reported	THC, 7-Amino Clonazepam

F	5.5	18	Suicide	None Reported	Caffeine, Cotinine, Diphenhydramine
F	2.4	18.35	Suicide	None Reported	Ethanol, Hydrocodone, Hydromorphone
F	6.6	28	Suicide	MDD	N/A
F	2	27	Suicide	MDD	N/A
F	2.1	17	Suicide	MDD	N/A
F	4	22	Suicide	MDD	N/A
M	6.7	14	Suicide	None Reported	Fluoxetine, Norfluoxetine
M	5.9	9	Suicide	None Reported	None
F	6.9	27.41	Suicide	OCD, Alcohol and Opioid Dependence	N/A
M	6.8	24.47	Suicide	MDD, ADHD	N/A
F	4.8	28	Suicide	MDD, OCD	N/A
M	5.9	19	Suicide	ASD, BD	N/A
<p>ADHD=Attention Deficit/Hyperactivity Disorder; MDD=Major Depressive Disorder; OCD=Obsessive Compulsive Disorder; ASD=Autism Spectrum Disorder; BD=Bipolar Disorder, N/A=Not Available.  Green-highlighted Subjects= iPSCs were generated from the dermal fibroblasts of these subjects.</p>					

Table ST2: Significant gene ontology (GO) terms (CorrectedPvalue $\leq$ 0.05; CorrectedMFPvalue $\leq$ 0.05) obtained through gene score resampling (GSR) method of ErmineJ (version 3.2) using the p-value from DESeq2 results (factor:~age+sex+RIN+group). ID=numerical ID of the GO term; Genes# =number of the genes in the GO term; RawScore=ErmineJ-derived score for the GO term; Pval=uncorrected p-value; CorrPvalue=FDR-corrected p-value; MFPvalue=multifunctionality p-value, CorrMFPvalue=p-value after multifunctionality correction; Multifunc=multifunctionality; Green=NPAS4-associated GO terms; Orange=ALDH1A2-associated GO terms; Blue=ALDH1A2- and NAAA-associated GO terms.

Name	ID	Genes #	RawScore	Pval	CorrPvalue	MFPvalue	CorrMFPvalue	Multifunc
Positive regulation of interferon-beta production	GO:0032728	38	1.21907837	1.00E-12	1.29E-09	3.89E-09	1.68E-06	0.802
Regulation of interferon-beta production	GO:0032648	55	1.09966104	1.43E-12	1.54E-09	3.10E-07	9.11E-05	0.843
Positive regulation of type I interferon production	GO:0032481	58	1.1062244	1.00E-12	2.15E-09	1.02E-06	2.44E-04	0.871
Negative regulation of viral genome replication	GO:0045071	44	1.15847562	2.58E-12	2.38E-09	1.44E-10	7.74E-08	0.702
Regulation of type I interferon production	GO:0032479	94	0.98294724	1.00E-12	3.23E-09	4.22E-06	9.10E-04	0.96
Pattern recognition receptor signaling pathway	GO:0002221	84	1.00485783	1.00E-12	6.46E-09	1.05E-04	1.38E-02	0.973
Toll-like receptor signaling pathway	GO:0002224	55	1.07259199	1.70E-11	1.37E-08	2.54E-04	2.78E-02	0.868
Negative regulation of viral process	GO:0048525	73	0.98206521	1.09E-10	7.80E-08	3.35E-07	9.41E-05	0.814
Regulation of viral genome replication	GO:0045069	69	0.91425383	5.69E-08	2.62E-05	4.27E-06	8.90E-04	0.836
Cellular response to xenobiotic stimulus	GO:0071466	54	0.91800513	2.19E-06	7.09E-04	2.27E-06	5.06E-04	0.898
Positive regulation of endothelial cell proliferation	GO:0001938	81	0.83095155	9.61E-06	2.59E-03	1.66E-05	2.91E-03	0.913
Digestive tract development	GO:0048565	40	0.9073861	3.71E-05	6.15E-03	1.00E-12	1.08E-09	0.887
Platelet activation	GO:0030168	48	0.87666977	4.79E-05	7.20E-03	1.78E-05	3.03E-03	0.839
Excitatory postsynaptic potential	GO:0060079	49	0.87707	4.69E-05	7.22E-03	5.83E-10	2.69E-07	0.89
Retinal metabolic process	GO:0042574	17	1.24282696	5.50E-05	8.08E-03	1.50E-05	2.69E-03	0.684
Cellular response to retinoic acid	GO:0071300	51	0.86224105	5.72E-05	8.22E-03	1.85E-10	9.20E-08	0.87
Midgut development	GO:0007494	6	1.87467553	6.00E-05	8.43E-03	7.50E-05	1.08E-02	0.744
Embryonic camera-type eye development	GO:0031076	11	1.36407656	1.75E-04	1.66E-02	4.00E-05	6.01E-03	0.608
Regulation of postsynaptic membrane potential	GO:0060078	76	0.7837523	2.31E-04	2.05E-02	1.54E-07	4.73E-05	0.906
Embryonic digestive tract development	GO:0048566	14	1.23906795	2.30E-04	2.06E-02	1.90E-04	2.19E-02	0.731
Response to retinoic acid	GO:0032526	88	0.76959343	2.60E-04	2.16E-02	1.61E-06	3.70E-04	0.969
Long-term memory	GO:0007616	35	0.89977609	2.69E-04	2.20E-02	1.16E-05	2.21E-03	0.838
Primary alcohol metabolic process	GO:0034308	62	0.80199472	3.66E-04	2.57E-02	1.00E-12	1.62E-09	0.9
Proximal/distal pattern formation	GO:0009954	17	1.12669608	3.90E-04	2.60E-02	1.25E-04	1.55E-02	0.723
Embryonic forelimb morphogenesis	GO:0035115	21	1.05611122	4.70E-04	2.87E-02	2.20E-04	2.49E-02	0.784
Retinoic acid biosynthetic process	GO:0002138	7	1.50579959	5.00E-04	2.99E-02	1.00E-12	3.23E-09	0.52
Forelimb morphogenesis	GO:0035136	25	1.00171502	7.00E-04	3.74E-02	4.60E-04	4.87E-02	0.792
Fc receptor signaling pathway	GO:0038093	44	0.84070362	7.31E-04	3.84E-02	9.06E-05	1.25E-02	0.883
Vitamin A metabolic process	GO:0006776	7	1.4515446	7.60E-04	3.93E-02	1.00E-12	2.15E-09	0.471

Table ST3: DESeq2 results for Differentially Expressed Genes (DEGs) in iPSC-derived hippocampal-like neurons (NPC vs Neurons). n=4 for both the NPCs and Neurons.

Gene symbol	P-value	FDR step up	Ratio	Fold change	LSMean (NPC)	LSMean (Neurons)	Change in Neurons
<b>Neuron Markers</b>							
MAP2	1.22E-10	7.27E-10	0.50	-2.00	20216.47	40372.30	Increased
DLG4	2.08E-13	1.73E-12	0.33	-3.07	1092.41	3356.51	Increased
TUBB3	7.76E-05	2.09E-04	0.46	-2.18	10699.69	23301.64	Increased
<b>Hippocampal Markers</b>							
ZBTB20	4.64E-06	1.50E-05	0.55	-1.82	2258.07	4102.88	Increased
LHX9	2.65E-02	4.42E-02	0.11	-8.70	99.49	865.57	Increased
ELAVL2	4.86E-05	1.35E-04	0.37	-2.72	1555.09	4223.59	Increased
TSPAN7	2.23E-31	1.02E-29	0.09	-10.67	341.84	3647.89	Increased
<b>CA1 Markers</b>							
POU3F1	2.45E-11	1.58E-10	3.72	3.72	671.81	180.51	Decreased
BCL11B	1.51E-04	3.88E-04	0.24	-4.17	121.61	506.50	Increased
WFS1	3.13E-01	3.88E-01	1.16	1.16	823.45	710.76	Unchanged
<b>CA2 Markers</b>							
PCP4	1.94E-26	5.78E-25	0.06	-17.20	21.92	376.90	Increased
RGS14	4.78E-05	1.33E-04	2.71	2.71	310.55	114.57	Decreased
<b>CA3 Markers</b>							
ELAVL2	4.86E-05	1.35E-04	0.37	-2.72	1555.09	4223.59	Increased
GRIK4	7.24E-24	1.71E-22	0.19	-5.15	97.73	503.64	Increased
SNAP91	1.25E-14	1.19E-13	0.08	-12.22	182.29	2228.27	Increased
SH3GL2	6.26E-26	1.77E-24	0.05	-20.24	73.48	1487.06	Increased
CADPS2	2.38E-10	1.37E-09	0.40	-2.50	403.03	1007.88	Increased
CHGB	1.18E-15	1.28E-14	0.20	-5.01	314.53	1575.08	Increased
CACNA1A	3.44E-07	1.32E-06	0.32	-3.16	102.71	324.72	Increased
LPL	1.30E-19	2.06E-18	16.51	16.51	23864.67	1445.89	Decreased
TGFB2	2.82E-04	6.87E-04	0.15	-6.55	470.78	3082.20	Increased
MYO5B	1.31E-11	8.74E-11	0.35	-2.88	363.62	1046.40	Increased
PKIA	5.83E-12	4.03E-11	0.29	-3.40	2909.73	9897.58	Increased
SNCA	1.29E-06	4.52E-06	0.38	-2.62	749.64	1963.01	Increased
SPOCK1	6.84E-12	4.69E-11	2.94	2.94	5093.39	1732.34	Decreased
HSPA2	6.78E-04	1.54E-03	0.36	-2.75	301.57	829.65	Increased
NEFL	2.39E-03	4.91E-03	0.60	-1.66	7239.41	12038.06	Increased
DKK3	3.68E-30	1.58E-28	0.23	-4.26	1705.69	7268.11	Increased
<b>DG Markers</b>							
PROX1	8.00E-02	1.18E-01	1.63	1.63	743.05	454.89	Unchanged



CALB1	5.27E-08	2.25E-07	5.55	5.55	6930.12	1248.18	Decreased
DOCK10	9.88E-12	6.66E-11	0.21	-4.81	475.82	2286.60	Increased

Table ST4: Differentially expressed genes (DEGs), determined by RNA-Sequencing (RNA-Seq), in iPSC-derived hippocampal-like NPCs of suicide deaths (CON vs Sui). n=2/group. Highlighted genes are common in both NPCs and neurons.

DESeq2 results for hippocampal-like NPCs (CON vs Sui), p≤0.05, FDR≤0.05						
Gene Symbol	P-value	FDR step up	Ratio	Fold change	LSMean(CON)	LSMean(Sui)
<i>SNORD3B-2</i>	5.29E-88	3.22E-84	0.02	-57.59	68.08	3920.73
<i>SNORD3B-1</i>	5.29E-88	3.22E-84	0.02	-57.59	68.08	3920.73
<i>RELN</i>	1.04E-12	4.23E-09	5.55	5.55	3215.45	579.00
<i>CRH</i>	8.39E-10	2.56E-06	5.00	5.00	866.32	173.37
<i>CNTN2</i>	3.78E-09	9.22E-06	4.23	4.23	3894.81	920.86
<i>H4C11</i>	2.68E-08	5.44E-05	0.29	-3.43	900.78	3092.58
<i>SCUBE1</i>	8.21E-08	1.43E-04	3.31	3.31	3370.64	1019.14
<i>EMX2OS</i>	3.19E-07	4.86E-04	4.28	4.28	1074.58	251.21
<i>PARM1</i>	6.48E-07	8.77E-04	2.91	2.91	2925.97	1004.88
<i>TMTC1</i>	2.13E-06	2.60E-03	2.51	2.51	3019.33	1201.43
<i>COL3A1</i>	3.03E-06	3.36E-03	0.50	-2.00	8849.73	17657.70
<i>HMCN1</i>	5.56E-06	5.52E-03	0.36	-2.76	597.42	1649.41
<i>CNTNAP2</i>	5.89E-06	5.52E-03	2.14	2.14	5905.46	2764.22
<i>EMX2</i>	7.54E-06	6.57E-03	4.24	4.24	587.40	138.49
<i>SCG2</i>	1.17E-05	9.50E-03	2.74	2.74	9006.52	3285.05
<i>OXTR</i>	2.49E-05	1.90E-02	3.41	3.41	515.49	151.01
<i>PDPR</i>	3.30E-05	2.20E-02	0.46	-2.16	1664.37	3588.05
<i>H2AC12</i>	3.65E-05	2.20E-02	0.53	-1.87	4910.13	9206.07
<i>COL8A1</i>	3.66E-05	2.20E-02	2.70	2.70	3610.26	1339.34
<i>BGN</i>	3.77E-05	2.20E-02	0.34	-2.93	255.28	748.74
<i>CCZ1</i>	3.79E-05	2.20E-02	2.23	2.23	2006.89	901.72
<i>BLACAT1</i>	4.06E-05	2.25E-02	3.49	3.49	688.16	197.13
<i>PRSS23</i>	5.16E-05	2.65E-02	1.85	1.85	13209.09	7147.09
<i>FBLN2</i>	5.40E-05	2.65E-02	0.45	-2.24	1125.37	2523.00
<i>ABCA1</i>	5.43E-05	2.65E-02	2.23	2.23	1888.39	847.99
<i>FZD5</i>	5.82E-05	2.73E-02	2.58	2.58	809.60	313.30
<i>IFITM2</i>	6.19E-05	2.78E-02	0.38	-2.62	793.15	2077.36
<i>UNC5D</i>	6.39E-05	2.78E-02	2.24	2.24	1654.83	738.10
<i>CCZ1B</i>	7.79E-05	3.28E-02	0.49	-2.06	1171.02	2407.12
<i>COL12A1</i>	9.57E-05	3.89E-02	0.39	-2.57	1172.34	3017.78
<i>VAV3</i>	1.10E-04	4.32E-02	2.39	2.39	1332.99	557.65

Table ST5: Differentially expressed genes (DEGs), determined by RNA-Sequencing (RNA-Seq), in iPSC-derived hippocampal-like Neurons of suicide deaths (Con vs Sui). n=2/group. Highlighted genes were common in both NPCs and neurons.

DESeq2 results for hippocampal-like neurons (CON vs Sui), $p \leq 0.05$ , $FDR \leq 0.05$						
Gene symbol	P-value	FDR step up	Ratio	Fold change	LSMean(CON)	LSMean(Sui)
<i>SNORD3B-2</i>	8.32E-31	5.89E-27	0.02	-40.71	35.19	1432.48
<i>SNORD3B-1</i>	8.32E-31	5.89E-27	0.02	-40.71	35.19	1432.48
<i>COL3A1</i>	1.11E-15	5.23E-12	0.22	-4.50	8656.00	38989.35
<i>COL1A1</i>	1.69E-15	5.97E-12	0.13	-7.51	2230.48	16757.22
<i>DCN</i>	4.03E-13	1.14E-09	0.21	-4.86	411.79	2003.27
<i>IGFBP3</i>	1.57E-11	3.70E-08	0.20	-5.12	229.47	1175.62
<i>COL5A1</i>	2.42E-11	4.89E-08	0.24	-4.22	944.15	3982.05
<i>HMCN1</i>	8.95E-11	1.54E-07	0.16	-6.15	113.60	698.99
<i>THBS1</i>	9.78E-11	1.54E-07	0.23	-4.28	525.45	2251.32
<i>LUM</i>	1.65E-10	2.33E-07	0.28	-3.57	1128.19	4029.03
<i>COL6A3</i>	1.96E-10	2.52E-07	0.18	-5.60	942.49	5279.06
<i>H4C11</i>	4.95E-08	5.83E-05	0.18	-5.57	197.46	1099.07
<i>PRRX1</i>	1.14E-07	1.18E-04	0.25	-4.02	168.74	678.51
<i>SNORD97</i>	1.23E-07	1.18E-04	0.27	-3.67	315.25	1156.59
<i>IFITM2</i>	1.25E-07	1.18E-04	0.23	-4.27	267.81	1144.73
<i>FBN2</i>	2.65E-07	2.35E-04	0.26	-3.83	499.27	1914.45
<i>IDI1</i>	3.70E-07	3.08E-04	0.27	-3.75	181.85	682.55
<i>POSTN</i>	5.68E-07	4.46E-04	0.21	-4.81	697.52	3351.59
<i>CYP26A1</i>	6.00E-07	4.46E-04	0.21	-4.72	100.56	474.93
<i>NOMO3</i>	7.90E-07	5.59E-04	0.20	-5.09	481.99	2455.69
<i>FBN1</i>	1.99E-06	1.34E-03	0.35	-2.86	745.52	2134.39
<i>MME</i>	4.39E-06	2.83E-03	0.17	-5.99	48.15	288.61
<i>MMP2</i>	5.46E-06	3.36E-03	0.25	-4.01	184.15	738.88
<i>PDGFRA</i>	6.62E-06	3.90E-03	0.33	-3.07	283.64	870.61
<i>MGP</i>	9.81E-06	5.55E-03	0.21	-4.86	69.97	339.72
<i>ALDH1A3</i>	2.90E-05	1.58E-02	0.15	-6.64	59.00	391.60
<i>COL5A2</i>	3.90E-05	2.04E-02	0.44	-2.28	3432.70	7821.19
<i>AQP1</i>	4.55E-05	2.30E-02	0.33	-2.99	396.99	1186.18
<i>CCZ1B</i>	5.12E-05	2.50E-02	0.42	-2.41	720.36	1734.82
<i>CXCL14</i>	9.87E-05	4.65E-02	0.14	-7.23	19.88	143.68
<i>NLRP2</i>	1.02E-04	4.65E-02	0.28	-3.58	117.21	419.51
<i>MXRA5</i>	1.05E-04	4.66E-02	0.23	-4.31	73.19	315.56
<i>TBR1</i>	1.11E-04	4.78E-02	6.39	6.39	165.84	25.95

## Materials and Methods

### RNA Extraction and Sequencing

The postmortem CA1 tissues were dissected out from the hippocampal formation and stored in RNAlater solution (ThermoFisher # AM7020) at  $-80^{\circ}\text{C}$  until RNA extraction. The total RNA was extracted from CA1 tissues using RNeasy Lipid Tissue Mini Kit (Qiagen # 74804) as per manufacturer's instructions. The total RNA from iPSC-derived NPCs and neurons were extracted using RNeasy Mini Kit (Qiagen # 74104). The RNA library preparation was carried out using Ribo-Zero Gold rRNA depletion and TrueSeq Stranded Total RNA Kit (Illumina, San Diego, USA). For 36 samples, 100 bp paired-end sequencing was performed on NovaSeq 6000 platform at the UCI Genomics High Throughput Facility (GHTF). For 14 samples, 125 bp paired-end sequencing was performed on HiSeq 2500 platform at the University of Utah High-Throughput Genomics. The number of read for each sample ranged from 27,277,523 to 65,709,547.

### Gene-level Differential Expression (DE) and Gene Ontology (GO) Analyses

Differentially expressed genes (DEGs) analysis was performed in Partek Flow, following five (5) steps: (1) rDNA and mtrDNA contaminants were filtered out from raw fastq files through Bowtie 2 (version 2.2.5). (2) Adaptor sequences were trimmed through Cutadapt-1.12. (3) Alignment of the fastq files was performed through TopHat 2 (version 2.1.0) with default settings [assembly: human-hg19, index: whole genome (administrator)]. (4) Annotation was performed with task "Quantify to annotation model (Partek E/M)" with assembly of human-hg19 and annotation model of RefSeq Transcript 93-2020-02-03. (5) Finally, differentially expressed genes (DEGs) were determined through DESeq2 with default settings. For CA1 tissue DEG analysis, features with minimum value of zero (0) was excluded before DESeq2 analysis. DESeq2 was run with factor of  $\sim\text{Age}+\text{Sex}+\text{RIN}+\text{Group}$  with default parameters. For DEG analysis in iPSC-derived hippocampal-like NPCs and neurons, features with minimum value of  $\leq 10$  were excluded from analysis before DESeq2. DESeq2 was run with default parameters with factors of  $\sim\text{Age}+\text{Group}$  (RIN was excluded because RIN was similar in all samples) in CON vs Sui comparison while factor of  $\sim\text{Age}+\text{Sex}+\text{Type}$  in NPC vs Neurons comparison. The gene ontology (GO) analysis was performed using the gene score resampling (GSR) method as implemented in the ErmineJ (Gillis, Mistry, & Pavlidis, 2010). GSR does not require a threshold for gene selection, but rather uses all the genes with their p-values. The full list of genes with their p-value from the DESeq2 (factor:  $\sim\text{age}+\text{sex}+\text{RIN}+\text{group}$ ) was used in the analysis. The following settings were used in the GSR analysis: aspect=biological process, maximum gene set size=100, minimum gene set size=5, maximum iterations=200,000.

### Dendritic Spine Morphology Analyses

Briefly, freshly dissected out hippocampal blocks ( $\sim 1\text{cm}^3$ ) were immersion fixed in freshly prepared cold 4% paraformaldehyde (in 0.1M Phosphate buffer (PB)) for 1 hour. After 1 hour of fixation, hippocampal blocks were post-fixed in 4% paraformaldehyde + 0.125% glutaraldehyde for 24 hours at  $4^{\circ}\text{C}$ . Later, 350  $\mu\text{m}$  coronal slices were obtained through vibratome (Leica VT1200). Microscopic 1,1'-diocetadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI)

crystals (Thermofisher # D282) were placed in CA1 regions and incubated in 0.1M PB at 37°C for 72 hours. Dendritic spine images were obtained through a Zeiss LSM 710 confocal microscope using a 63 x oil immersion objective (NA=1.4). The acquired images of dendritic spines were deconvolved using AutoQuant X3 (Bitplane, RRID:SCR\_002465) and three-dimensional dendritic spine modeling was performed using Neurolucida 360 (MBF Bioscience, RRID:SCR\_016788). 2-3 dendritic segments were analyzed per neuron for both apical and basal dendrites.

#### Conversion of Skin Fibroblasts into iPSC:

Briefly, dermal fibroblasts were grown from skin biopsies and maintained in fibroblasts media [DMEM, FBS (10%), MEM NEAA, Na-Pyruvate, GlutaMAX, Penicillin-Streptomycin and beta-mercaptoethanol]. Fibroblasts (in fibroblasts media) were transfected with three episomal plasmids expressing human OCT3/4 and shRNA against p53 (Addgene# 27077: pCXLE-hOCT3/4-shp53-F), L-MYC and LIN28 (Addgene# 27080: pCXLE-hUL), SOX2 and KLF4 (Addgene# 27078: pCXLE-hSK). Fibroblasts ( $1 \times 10^6$  cells, in fibroblasts media), less than 5 passages, were electroporated with 3  $\mu\text{g}$  of each episomal plasmid through Neon<sup>TM</sup> Transfection System 100  $\mu\text{L}$  kit (MPK10096, Thermo Fisher Scientific, MA, USA) according to manufacturer protocol. Neon<sup>TM</sup> transfection conditions were 1650 V, 10 ms and 3 pulses. Seven-days post-transfection, fibroblasts were replated onto 6-well plates containing mitomycin C-inactivated mouse embryonic fibroblasts (MEF) feeder cells. Next day, fibroblasts media was switched to iPSC media [DMEM/F12 with 20% KOSR, 3% ESC-quality FBS, 20 ng/ml bFGF, 1mM GlutaMAX, 100  $\mu\text{M}$  MEM NEAA, 100  $\mu\text{M}$  2-mercaptoethanol, and penicillin-streptomycin] which was changed every day until iPSC colonies were ready to be picked. Colonies were manually picked 21 days post-transfection and maintained on Vitronectin XF (Stemcell Technologies Inc, #07180) coated wells with mTeSR Plus feeder-free media (Stemcell Technologies Inc, #100-0276). Pluripotency of iPSCs were characterized through immunostaining of pluripotency markers OCT4, SOX2, SSEA4 and TRA-1-60 (A24881, Thermo Fisher Scientific, MA, USA).

#### Generation of Hippocampal-like Neural Precursor Cell (NPC) and Neurons:

Briefly, iPSCs were mechanically dissociated and transferred to low-attachment cell culture plates with mTeSR Plus media (with the addition of ROCK inhibitor, 10  $\mu\text{M}$ ) to form embryoid body (EB). After two days, mTeSR Plus media was replaced with N2/B27 media [DMEM/F12/GlutaMax/N2/B27(w/o vitamin A) /Penstrep] supplemented with DKK1 (0.5  $\mu\text{g}/\text{mL}$ ), SB431542 (10  $\mu\text{M}$ ), Noggin (0.5  $\mu\text{g}/\text{mL}$ ) and cyclopamine (1  $\mu\text{M}$ ) (maintained for 10 days). After 10 days, EBs were transferred onto poly-ornithine/laminin coated plates with N2/B27 media plus laminin (1  $\mu\text{g}/\text{mL}$ ). Once rosettes formation was visible, EBs were mechanically dispersed and maintained in N2/B27 media supplemented with 20 ng/mL human basic fibroblasts growth factor (b-FGF) to obtain hippocampal-like NPC. To obtain hippocampal-like neurons, NPCs were plated onto poly-ornithine/laminin coated plates and maintained in neuronal differentiation media [N2B27 media + ascorbic acid (200  $\mu\text{M}$ ) + dibutyryl cyclic-AMP (400  $\mu\text{M}$ ) + BDNF (20 ng/mL) and Wnt3A (5 ng/mL). Wnt3A was discontinued after three weeks and the differentiation was maintained for two more weeks. The iPSC-derived neurons were characterized through RNA-Seq and immunocytochemistry (ICC). The following primary antibodies were used:

MAP2 (ZRB2290, Sigma-Aldrich), beta-Tubulin-III (Tuj1) (801202, BioLegend), vGluT1 (821302, BioLegend), PSD95 (MA1-045, Thermofisher), GABA (A2052, Sigma-Aldrich), GRIK4 (NBP1-76852, Novus Biologicals), PROX1 (925202, BioLegend), and CTIP2 (650601, BioLegend).

#### References:

Gillis, J., Mistry, M., & Pavlidis, P. (2010). Gene function analysis in complex data sets using ErmineJ. *Nat Protoc*, 5(6), 1148-1159. doi:10.1038/nprot.2010.78